J&J Is Spitzer's Next Target: New York AG Opens Broad Off-Label Promotion Investigation
This article was originally published in The Pink Sheet Daily
Executive Summary
Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.
You may also be interested in...
Remicade Sales Aid Makes Misleading Efficacy Claims, FDA Tells J&J
Sales aid improperly suggests the TNF-inhibitor can reverse or heal the disease process in patients with early rheumatoid arthritis, an FDA ad division “untitled” letter states. Agency also cites the promotion for omitting risk information. Centocor says the sales aid has not been used since October.
Remicade Sales Aid Makes Misleading Efficacy Claims, FDA Tells J&J
Sales aid improperly suggests the TNF-inhibitor can reverse or heal the disease process in patients with early rheumatoid arthritis, an FDA ad division “untitled” letter states. Agency also cites the promotion for omitting risk information. Centocor says the sales aid has not been used since October.
Pfizer Under Investigation By New York AG Spitzer
Pfizer is under investigation by the New York State Attorney General for possible off-label promotion